FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news